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Background. Acute renal failure (ARF) is traditionally consid-
ered a poor prognostic factor in end-stage liver disease and is
associated with a mortality approaching 90%. While the increased
use of orthotopic liver transplantation (OLTX) has changed the
outcome for patients with end-stage liver disease (ESLD), it is not
clear whether this has affected the outcome of patients with
ESLD and ARF.
Methods. We prospectively followed the course of ARF in 177
patients with ESLD being evaluated for OLTX. Of these patients
111 received OLTX. In-hospital mortality was compared to that of
316 ESLD patients without ARF, of these 196 received OLTX.
Variables include severity of illness as assessed by APACHE II,
co-morbid conditions, oliguria, need for renal replacement ther-
apy, and etiologies of ESLD and ARF. These variables were
evaluated with respect to the outcome in-hospital mortality by
multiple regression analysis for patients with ARF.
Results. Mortality was significantly higher in oliguric versus
non-oliguric patients and in patients who required renal replace-
ment therapy. Mortality correlated strongly with the number of
co-morbid conditions, especially sepsis, encephalopathy, respira-
tory failure, and DIC. For OLTX recipients who developed ARF,
no significant difference in survival occurred whether the ARF
was pre-OLTX or post-OLTX.
Conclusion. ARF was associated with an increased mortality
consistent with the known adverse prognostic effect of ARF in
ESLD. However, the effect of ARF on mortality was remarkably
reduced in patients who received a functioning OLTX. Since
expected mortality generated from APACHE II scores was higher
in the ARF groups, it is not clear that there is an additional effect
of ARF beyond the physiologic derangements captured by
APACHE II. ARF per se should not necessarily be a contraindi-
cation to liver transplant.
End stage liver disease (ESLD) is a common disorder of
multiple etiologies for which the only effective therapy is
orthotopic liver transplantation (OLTX) [1, 2]. Patients
with ESLD often incur acute episodes of critical illness and
frequently develop renal complications including acute
renal failure (ARF). ARF in patients with ESLD may be
due to hepatorenal syndrome [1] or secondary to any of the
etiologies typically associated with ARF in the critically ill
such as sepsis or ischemia [1, 3, 4]. ARF in the critically ill
is associated with a persistent high mortality despite the
institution of renal replacement therapy [5–10], and this
mortality is thought to be largely due to the co-morbid
conditions in these patients [3, 6–9]. Patients with ESLD
appear to have a particularly high mortality in the presence
of ARF [4]. The possibility of organ transplantation obvi-
ously changes this impact by potentially removing a major
co-morbid condition. The increasingly widespread applica-
tion of OLTX results in a potentially new subset of ARF
patients where the relationship between underlying co-
morbidity and outcome may be dramatically altered. The
outcome of ARF in patients with OLTX has been variously
described as better, worse, or similar to that seen in other
groups of critically ill patients [1–3, 11–14]. We explored
the relationship between ARF, ESLD and OLTX in a
cohort of 493 patients with ESLD. We examined the course
and treatment of ARF in 177 patients with ESLD (111 or
63% of whom received OLTX) and compared outcomes to
316 ESLD patients without ARF (196 or 62% of whom
received OLTX) to determine the influence of ARF on
mortality in this setting (Fig. 1). We sought to describe the
incidence and natural history of ARF in ESLD in the
presence or absence of OLTX. In addition, we wanted to
determine whether the predictive value of a standard
measure of illness severity (APACHE II) is affected by
OLTX in the presence or absence of ARF.
METHODS
Over an 18 month period, 493 patients with ESLD were
admitted to the University of Pittsburgh Medical Center for
evaluation and possible OLTX. Data were collected pro-
spectively on 177 patients with parenchymal acute renal
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failure seen and evaluated by the Renal Service. Three
hundred and sixteen in-patients with ESLD who were
contemporaneously evaluated for OLTX but did not de-
velop ARF during the same time period were identified by
a review of electronic medical archival record system. ARF
was defined as a doubling of serum creatinine over 24 hours
or the acute onset of oliguria requiring initiation of renal
replacement therapy. Patients were not defined as ARF if
the sole cause of functional deterioration was pre-renal
azotemia, defined as azotemia that reversed within two
days of intravascular volume resuscitation. Patients who
were dialysis dependent at admission secondary to chronic
renal failure of any cause and patients who underwent
multi-visceral transplants were excluded from the analysis.
Etiologies of ARF were determined on clinical grounds at
the time of initial evaluation. In many patients, more than
one potential etiology was identified. Hepatorenal syn-
drome was defined as progressive renal failure with dou-
bling of the serum creatinine and oliguria with urine
sodium concentration less than 10 mEq/liter that did not
reverse with intravascular volume repletion in ESLD pa-
tients. Oliguria was defined as urine output less than 400
ml/24 hours. Dialysis support was initiated for standard
indications in the setting of ARF [5] and was either
standard hemodialysis (HD) using cellulose acetate dialyz-
ers or continuous renal replacement therapy (CRRT) using
polyacrylonitrile hemofilters. CRRT was primarily contin-
uous venovenous hemodialysis (CVVHD) [15]. Choice of
dialysis mode was made on clinical grounds and CRRT was
primarily used for those patients whose blood pressure,
even with pressor support, was deemed insufficient to
support standard hemodialysis. Some patients received
both modes. This could occur in two settings: either the
patient’s hemodynamic profile improved to the point that
standard hemodialysis could be substituted, or it deterio-
rated to the point where CRRT was required.
Patients, including those without ARF, were scored by
APACHE II [16, 17] on ICU admission. This was per-
formed by trained scorers with internal cross-checks for
validity. Some patients did not receive APACHE II scores,
either because they were never in the ICU or the data could
not be retrieved. Overall, 80% of patients were scored
using APACHE II. In terms of subgroups analyzed the
following percentage received scoring: ARF patients 70%,
OLTX patients without ARF 90%, and non-ARF, non-
OLTX patients 71%. Predicted death rates (PDR) were
calculated for all patients with APACHE II scores using
standard APACHE II methodology [17]. Standardized
mortality rates (SMR) were calculated as the ratio of
observed to predicted mortality for those patients who
received APACHE II scores. These were taken to be
representative of the entire group or any subgroup of
Fig. 1. Patient populations with end-stage liver disease
(ESLD). APACHE II scores were calculated as per the
Methods section.
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patients since in no case was the observed mortality for the
entire cohort significantly different from that seen in those
scored for APACHE II.
The primary outcome parameter used in this study was
in-hospital mortality. Long-term outcome data were ob-
tained from outpatient clinic charts. Follow-up time on
survivors was 6 to 18 months. Results are reported as the
mean 6 the standard error. Analysis of data were by the X2
test for proportional categorical data, Student’s t-test for
continuous data samples, multiple regression analysis, Cox
Proportional Hazard and stepwise logistic regression where
indicated. Statistics were performed using NCSS (Number
Cruncher Statistical System). Significance was taken at
P , 0.05.
RESULTS
Overall, 493 patients with decompensated ESLD were
evaluated. The hospital mortality for this group was 31%;
307 of these patients underwent OLTX and had an in-
hospital mortality of 17%. The remaining 186 did not
receive a transplant during this hospitalization, and their
hospital mortality was 54%, typical of the grim outcome
described for this entity without transplantation. ARF
occurred in 94 patients while awaiting transplantation, for
an incidence of 19%. Sixty-six of these patients did not
receive an OLTX, and 28 of these patients were trans-
planted with ongoing ARF. Of the remaining 279 patients
transplanted, ARF developed in 83 during the post-trans-
plant period, for an incidence of 30%. These data indicate
that ARF is a frequent complication in this critically ill
group of patients, with or without transplantation.
The characteristics of the patients with respect to their
status as either ARF or transplant recipients are indicated
in Table 1. There was no difference in age or sex distribu-
tion between the four groups. Patients with ARF had
greater severity of illness at time of evaluation as indicated
by higher mean APACHE II scores (P , 0.01), irrespective
of transplant status. Similarly, ARF was associated with a
higher mortality in both transplanted and non-transplanted
patients compared to the respective control groups without
ARF.
Patients with ARF were analyzed in relation to whether
or not they received OLTX. Additionally, patients who
received OLTX were divided into those who developed
ARF prior to or following transplantation, to determine
whether the pattern and outcome of ARF developing at
these times was different. Descriptive features of 177
ESLD patients with ARF are shown in Table 2. The mean
baseline serum creatinines were similar in all groups, but
ARF patients who did not receive OLTX had higher mean
APACHE II scores (P , 0.02) and a greater number of
identified co-morbid conditions (P , 0.02) than either of
the OLTX groups, explaining to some degree why they did
not receive OLTX. Patients who developed ARF post-
OLTX were less frequently oliguric (P , 0.005) and could
more frequently be managed without dialysis (P , 0.02)
than the other groups. This may relate to differences in
etiology as shown in Table 3. The majority of patients in all
groups, however, required some type of dialysis support
during their course, most commonly CRRT. In all, 77% of
patients identified by our criteria required renal replace-
ment therapy, suggesting that we have identified patients
with severe parenchymal ARF.
Potential etiologies of ARF identified in patients are
shown in Table 3. Many patients had more than one
potential etiologic factor involved, however, there are
certain interesting differences between the groups. In all
groups, the most common etiology identified for ARF was
Table 1. Demographics of end-stage liver disease (ESLD) patients
OLTX,
ARF
No OLTX,
ARF
OLTX,
No ARF
No OLTX,
No ARF
N 111 66 196 120
Age, years 50.5 6 1 52.3 6 1.5 50.7 6 0.9 52.8 6 1.3
Male 34% 49% 54% 58%
APACHE II score 23.2 6 0.8a 27 6 1.2a 16.2 6 0.4a 18.1 6 0.8a
Mortality 38% 86% 5% 36%
Abbreviations are: OLTX, orthotopic liver transplantation; ARF, acute
renal failure.
a All significantly different at P , 0.01.
Table 2. Characteristics of ARF patients
OLTX,
ARF pre
OLTX,
ARF post
ARF, No
OLTX
N 28 83 66
Baseline SCr 1.4 6 0.1 1.4 6 0.05 1.6 6 0.1
APACHE II scores 25.6 6 1.4 22.4 6 0.8 27.3 6 1.2a
# co-morbid diseases 2.8 6 0.5 2.9 6 0.2 4.4 6 0.2a
% With oliguria 54% 35% 58%b
Dialysis
None 7% 31% 18%a
HD 36% 22% 17%
CRRT 57% 47% 65%a
Abbreviations are: ARF, acute renal failure; OLTX, orthotopic liver
transplantation; APACHE, Acute Physiology and Chronic Health Evalu-
ation; HD, hemodialysis; CRRT, continuous renal replacement therapy.
a P , 0.02 compared to OLTX, ARF pre and OLTX, ARF post.
b P , 0.005 compared to OLTX, ARF post.
Table 3. Etiology of ARF in an ESLD with ARF patient population,
(N 5 177)
OLTX,
ARF pre
OLTX,
ARF post
ARF, No
OLTX
ATN, ischemic 54% 52% 53%
ATN, nephrotoxic 21% 18% 14%
FK/cyclosporine toxicity 0 40% 0
Hepatorenal syndrome 43% 8% 49%
Contrast nephropathy 8% 7% 14%
Sepsis 11% 2% 11%
Rhabdomyolysis 4% 1% 0
Note: patients may have multiple etiologies. Abbreviations are: ATN,
acute tubular nephrosis; FK, FK-506; ARF, acute renal failure; OLTX,
orthotopic liver transplantation.
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ischemia. This etiology was identified when there existed
documented sustained hypotensive episodes prior to the
evolution of ARF. The contribution of the nephrotoxic
immunosuppressive agents to ARF was reserved for those
patients who developed ARF post-transplant. The second
most common cause of ARF in both groups who developed
ARF prior to transplant (or never received transplant) was
hepatorenal syndrome. This is by definition oliguric and
may explain why oliguria was less commonly seen in
patients who developed ARF post-OLTX. Several patients
in this group were identified as hepatorenal ARF, and
these patients were those in which graft function was poor.
Etiologies of ESLD found in the three ARF groups were
compared to assess whether this might influence outcome.
There were no significant differences between the under-
lying liver diseases in these patient groups. The most
common cause of ESLD for all groups was alcoholic liver
disease followed by ESLD secondary to hepatitis C, cryp-
togenic cirrhosis and hepatitis B.
All patient groups were monitored for development of
co-morbid conditions during their course. Table 4 indicates
the distribution of co-morbid conditions between the three
groups of ARF patients. Patients who did not receive
OLTX had the most severe degree of co-morbidity as
shown here and in Table 2. These patients were, to some
degree, less likely to be considered for receiving OLTX
because of their critical state. Nevertheless, critical compli-
cations also occurred at a very high frequency in the two
ARF groups who received OLTX.
Outcome for the ARF groups with respect to severity of
their underlying ARF is shown in Table 5. Overall mortality
was highest in those patients who did not receive OLTX.
There was a trend towards a lower mortality in patients who
developed ARF pre-OLTX compared to those who devel-
oped it following OLTX, but this did not reach statistical
significance. Oliguria and the need for renal replacement
therapy were generally associated with higher mortalities,
however, the highest mortalities in each group were seen in
patients who required CRRT.
In an effort to determine what conditions associated with
ARF may have contributed to mortality, multiple logistic
regression analysis was performed using all the previously
described clinical information (demographics, etiologies,
oliguria, need for dialysis, co-morbid conditions, APACHE
II scores) with survival as the dependent variable. For all
ARF patients, this analysis suggested that the number of
co-morbid conditions correlated best with outcome
(P , 0.001). Co-morbid conditions significantly associated
with outcome were sepsis, hepatic encephalopathy, and
DIC (all P , 0.0001). To increase the sensitivity of this
analysis, it was repeated using stepwise regression on the
subgroups of patients who developed ARF with OLTX
(either pre- or post-OLTX) and those with ARF without
OLTX. According to this analysis, mortality in ARF pa-
tients with OLTX correlated with requirement for dialysis,
and the co-morbid conditions sepsis and DIC. Mortality for
ARF patients without OLTX was correlated with the
etiology fulminant hepatic failure, APACHE II scores, and
the co-morbid conditions hepatic encephalopathy, DIC,
myocardial infarcts and pulmonary emboli.
There were 78 patients with ARF who were discharged
alive, the vast majority (92%) of whom received OLTX. To
determine the impact on long-term renal function of ARF
under these conditions, we evaluated these patients at 6 to
18 months follow-up. Ninety percent of the patients recov-
ered renal function with a mean serum creatinine of 1.7%.
This indicates a surprisingly good outlook for patients with
ARF who survive OLTX. It has previously been suggested
that this is particularly true of patients with ARF secondary
to hepatorenal syndrome [1]. We identified a total of 44
patients with hepatorenal syndrome prior to transplant of
whom only 12 were transplanted. Four of these patients
died, for a hospital survival of 57%, not significantly
different from the 83% survival for all transplanted pa-
tients. Patients who were transplanted with HRS did quite
well in spite of a high degree of co-morbidity averaging 7.5
co-morbid conditions and with mean APACHE II scores of
26.3 6 13. Patients with HRS who were not transplanted
had the expected poor outcome (91% mortality). Finally,
we sought to evaluate the ability of APACHE II to predict
mortality in this group of patients [3, 16–19]. Standardized
mortality rates close to 1 indicate good concordance be-
tween observed and predicted mortality. As shown in
Table 4. Co-morbid conditions (N 5 177)
OLTX,
ARF pre
OLTX,
ARF post
ARF, No
OLTX
Sepsis 43% 58% 76%
Hepatic encephalopathy 43% 55% 92%
Intra-abdominal infection 43% 46% 47%
Respiratory failure 50% 43% 77%
DIC 32% 37% 74%
GI bleeding 46% 36% 56%
MI 11% 5% 12%
Pulmonary embolism — 7% 2%
CVA 11% 2% 5%
Abbreviations are: OLTX, orthotopic liver transplantation; ARF, acute
renal failure; DIC, disseminated intravascular coagulation; GI, gastroin-
testinal; MI, myocardial infarction; CVA, cerebral vascular accident.
Table 5. Mortality in ARF patients (N 5 177)
OLTX,
ARF pre
OLTX,
ARF post
No OLTX,
ARF
Mortality
Overall 29% 41% 86%a
With oliguria 27% 52% 92%a
Without oliguria 31% 35% 79%a
No dialysis 0 15% 67%a
HD 10% 22% 64%a
CRRT 44% 67% 98%a
Abbreviations are in Table 2.
a P , 0.002 compared to OLTX, ARF pre and OLTX, ARF post
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Figure 2, standardized mortality rates were close to 1 for
virtually all groups examined. Standardized mortality rates
tended to be greater than 1 in the ARF groups, and were
substantially lower than one only in the patients who
received OLTX but did not develop ARF. This is consistent
with previous observations that successful OLTX alters the
relationship between APACHE II and outcome in a favor-
able direction (that is, patients do better than predicted)
[19, 20]. Data shown here suggest that that may not be the
case in patients who develop ARF. To examine this further,
we calculated mortality and standardized mortality rates in
all OLTX recipients who developed ARF (either pre- or
post-OLTX). Table 6 demonstrates the influence of dialysis
modality on survival and SMR. The overwhelming majority
of the mortality is in patients who required CRRT. Patients
who required no dialysis or could be supported with
standard hemodialysis, did very well and had an SMR well
below 1, similar to OLTX patients who did not develop
ARF.
DISCUSSION
ARF in the critically ill is associated with a high mortality
that has not improved substantially over several decades
[6–10]. Consistent with this observation, a recent evalua-
tion of ARF at this institution [3] demonstrated a mortality
of 50% which correlated well with illness severity as
assessed by APACHE II. Examination of these outcomes in
more detail revealed a mortality of 34% in transplant
recipients with ARF compared to a 62% mortality in
non-transplanted patients [3]. This suggested that ARF
might have different characteristics and course, or an
altered relation between co-morbidity and outcome, in
transplant recipients compared to other critically ill pa-
tients. We sought to examine this possibility with a prospec-
tively followed group of ARF patients whose co-morbid
conditions were well defined.
Table 6. Outcomes of ARF in OLTX recipients by dialysis modality
N APACHE II Mortality SMR
OLTX, no dialysis 28 21.5 6 0.15 11% 0.46
OLTX, hemodialysis (HD) 28 21.8 6 1.3 17% 0.68
OLTX, CRRT 55 24.5 6 12.3a 59%b 1.82
Abbreviations are in the Appendix.
a P 5 0.02 compared to OLTX no dialysis.
b P , 0.0001 compared to OLTX no dialysis and OLTX HD.
Fig. 2. Outcomes and standardized mortality
rates for end-stage liver disease (ESLD)
patients. Standardized mortality rate (SMR)
calculated as the ratio of the observed mortality
to the predicted by APACHE II scores.
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The definition of ARF used in this study was a doubling
of serum creatinine within 24 hours or acute oliguria with
the need for dialysis. We have previously used this defini-
tion to characterize a population with parenchymal ARF
[3] and to exclude patients with pre-renal azotemia or the
moderate chronic renal insufficiency almost universally
seen in the post-transplant period in patients receiving
FK-506 or cyclosporine [21]. Even with this definition, ARF
was a frequent complication of ESLD with or without
OLTX. In both circumstances, ARF was associated with a
marked increase in mortality, and was seen in patients with
higher severity of illness scores (APACHE II) and a high
number of co-morbid conditions.
Etiologies of ARF were typical of those described for
critically ill patients [3, 6–10] except for the high frequency
of HRS in untransplanted patients and the association with
immunosuppressive drug toxicity in transplanted patients.
ARF was less frequently oliguric in OLTX patients than in
untransplanted patients, consistent with the previous com-
parisons between transplanted and general medical-surgi-
cal ARF [3]. The majority of patients required dialysis
support and the most common modality employed was
CRRT. This reflects both the high degree of co-morbidity
seen in this ARF population and the general hemodynamic
instability associated with ESLD. There was no significant
difference in outcome for recipients of OLTX who devel-
oped ARF pre versus post transplantation. Hospital sur-
vival for patients with ARF pre-transplant was surprisingly
good, particularly when viewed in the perspective of the
almost universal mortality of ARF in ESLD patients with-
out OLTX. This was true irrespective of etiology, and
patients with hepatorenal syndrome (HRS) pretransplant
did equally as well as patients with other etiologies of ARF
preOLTX. It has previously been reported that outcome
for patients with HRS pretransplant was not different from
that of patients without HRS [1]. We would concur with the
previous suggestions that HRS specifically or ARF in
general should not preclude transplantation [1]. In our
study, the in-hospital survival among all patients receiving
OLTX was 83%. We did not have access to follow-up data
beyond hospital discharge for our non-ARF cohort. How-
ever, one month survival for all patients who received
OLTX has been reported as 84%, falling to 76% at one
year [22]. Though we do not have one year follow-up on the
entire population, hospital mortality presumably reflects
the vast majority of deaths in our cohort, since it was shown
in the national UNOS registry that the highest likelihood of
dying occurred within one month of transplant [22]. The
observation that mortality was higher among OLTX recip-
ients who experienced ARF post-transplant is consistent
with the previous observations [23].
Regression analysis of clinical factors associated with
mortality in the ARF patients tended to support the
intuitive observation that the primary determinant was
co-morbidity. Demographic factors and etiologies of either
ESLD or ARF did not emerge as significant determinants
of outcome. The highest correlation to mortality was seen
with the higher mean number of co-morbid conditions and
with the particular co-morbid condition, sepsis. It is likely
that this factor contributed to outcome in more than one
way. For untransplanted patients, sepsis would tend to
preclude transplantation, while following transplantation,
sepsis would occur in the setting of immunosuppression.
Severity of illness as assessed by APACHE II predicted
outcome quite well in the majority of patients, with stan-
dardized mortality rates close to 1. Standardized mortality
rates differed most from unity in patients who developed
ARF post-OLTX, and in patients who underwent OLTX
and never developed ARF. Patients with OLTX without
ARF did extremely well with a hospital mortality of only
5%. To some extent this represents a selection bias since
these patients had the lowest mean APACHE II scores of
all groups examined. Nevertheless, the APACHE II scores
markedly over-predicted mortality in this group (Fig. 2).
We and others have previously suggested that transplanta-
tion changes the relationship between APACHE II scores
and outcome by removing a major co-morbid condition
[19]. The current observation is consistent with this sugges-
tion. In contrast, APACHE II scores appeared to under-
predict mortality in those OLTX patients who developed
ARF post-transplant, and this is not consistent with the
above hypothesis unless ARF has an overriding effect on
outcome. This was examined further by examining the
outcomes of ARF patients as a function of severity of
illness, stratified in this case by the type of dialysis support
required. All ARF patients who received OLTX were
analyzed. Patients who did not require dialysis or who could
be successfully managed by hemodialysis alone had similar
mean APACHE II scores, low mortalities, and standard-
ized mortality rates well below unity, similar to OLTX
patients without ARF, albeit with small numbers. This
suggested that ARF, per se, did not have an overriding
effect on outcome. Patients with ARF who required CRRT
had both higher mean APACHE scores and an even higher
mortality than predicted by these scores. We suggest that in
this population at least, the major impact on mortality in
ARF is supplied by the hemodynamic status (which is not
captured by the APACHE II scoring system) severe enough
to require CRRT for renal replacement therapy, which
correlates with sepsis as a major contributing co-morbid
condition.
In conclusion, our data demonstrate that ARF is a
frequent complication of ESLD with or without OLTX.
ARF markedly increases mortality in both cases. In patients
who do not receive OLTX, ARF is associated with a 90%
in-hospital mortality, similar to that previously described
but excessive beyond the prediction by APACHE II scores
[17]. ARF occurring in patients who receive OLTX is
associated with an increased mortality primarily associated
with co-morbidity and particularly the requirement for
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CRRT. Nevertheless, the outcome of ARF in these pa-
tients is superior to that described in the literature for other
types of critically ill patients [3]. Patients with ARF pre-
transplant do not have a substantially worse outcome than
that observed for all OLTX patients, suggesting that this
single factor should not preclude transplantation. Long-
term outcome for survivors of ARF associated with OLTX
is good, with the majority recovering renal function.
Reprint requests to John P. Johnson, M.D., 937 Scaife Hall, University of
Pittsburgh School of Medicine, 3550 Terrace Street, Pittsburgh, Pennsylvania
15213-2500, USA.
APPENDIX
Abbreviations used in this article are: APACHE, Acute Physiology and
Chronic Health Evaluation Score; ARF, acute renal failure; CRRT,
continuous renal replacement therapy; CVVHD, continuous venovenous
hemodialysis; DIC, disseminated intravascular coagulation; ESLD, end-
stage liver disease; HRS, hepatorenal syndrome; OLTX, orthotopic liver
transplant; SMR, standardized mortality rates;
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